Infection is a major source of morbidity and the leading cause of death in immunocompromised patients \[[@B1]\]. The increased susceptibility to infection results from the intertwined effects of the immunocompromising condition, treatments, and co-morbidities \[[@B1]\]. Human infection with the novel H1N1 influenza virus was first recognized in early April 2009 and declared a worldwide pandemic by the World Health Organization in June 2009. Recent case series provide information on the clinical course, risk factors, and outcome of H1N1(v) infection \[[@B2]-[@B4]\]. Both New Zealand and Canada have experienced H1N1(v) outbreaks with severe illness requiring intensive care unit (ICU) admission, ventilatory support, and rescue therapies. However, no case series have specifically described the features of H1NI(v) infection in immunocompromised patients. Here, we report the clinical and epidemiologic features in 10 critically ill immunocompromised patients with H1N1(v) infection.

The case definition was ICU admission for acute respiratory failure and a positive specific polymerase chain reaction test for the pandemic influenza A (H1N1) 2009 virus. All patients meeting this case definition were included.

In late 2009, 15 patients with H1N1-related acute respiratory failure, including 10 immunocompromised patients, required ICU admission. As reported in Table [1](#T1){ref-type="table"}, median time from respiratory symptom onset to ICU admission was 4 days (interquartile range \[IQR\] 3 to 5 days). Hypoxemia was mild at ICU admission but worsened over the next few days. The chest radiographs consistently showed extensive pulmonary infiltrates (median Murray score 3; IQR 2 to 4), and 80% of cases showed an alveolar pattern. All patients were treated with oseltamivir, which was prescribed 1 day (range 0 to 6 days) after ICU admission. Superinfection (mostly bacterial pneumonia) occurred in all patients in keeping with previous data on seasonal influenza \[[@B5]\]. The clinical course was characterized by prolonged oxygen dependency in the survivors (10 days; IQR 6 to 15 days). Death occurred in four patients and was usually secondary to severe hypoxemia.

###### 

Clinical characteristics and outcomes of H1N1(v) critically ill immunocompromised patients

  Patient   Type of immune deficiency                  Chemotherapy   Immuno- suppressive agents   Lymphocyte count   Time, in days, from respiratory symptoms to ICU admission   Ventilatory support   Superinfection                               Anti-infectious agents^a^   Outcome
  --------- ------------------------------------------ -------------- ---------------------------- ------------------ ----------------------------------------------------------- --------------------- -------------------------------------------- --------------------------- ---------
  1         Chronic myeloid leukemia                   No             No                           4,000              3                                                           NIV                   Clinically documented                        C3G/macrolide               Alive
  2         Allogeneic BMT (12 months ago) with GVHD   No             Yes (steroid/CIs)            800                1                                                           MV                    Clinically documented                        Piperacillin/FQ             Dead
  3         Allogeneic BMT (15 months ago) with GVHD   No             Yes (steroid/CIs)            600                1                                                           NIV                   *Escherichia coli + Aspergillus fumigatus*   Imipeneme/FQ                Dead
  4         Autologous BMT for multiple myeloma        Yes            Yes (steroid)                50                 5                                                           None                  Clinically documented                        Piperacillin/macrolide      Alive
  5         Renal transplantation                      Yes            Yes (steroid/CIs/MMF)        1,200              5                                                           MV                    *Pseudomonas aeruginosa*                     Piperacillin/macrolides     Dead
  6         HIV                                        No             No                           1,800              3                                                           None                  *Streptococcus pneumoniae*                   C3G/macrolide               Alive
  7         Autologous BMT for multiple myeloma        Yes            Yes (steroid)                100                5                                                           MV                    Clinically documented                        Piperacillin/macrolide      Alive
  8         Myelodysplasia                             Yes            Yes (steroid)                2,000              3                                                           MV                    *E. coli*                                    Piperacillin/macrolide      Dead
  9         Mantle cell lymphoma                       No             No                           100                2                                                           NIV and MV            *S. pneumoniae*                              C3G/macrolide               Alive
  10        Solid organ transplantation                No             Yes (steroid)                2,000              2                                                           None                  *S. pneumoniae*                              C3G/macrolide               Alive

^a^All patients were receiving oseltamivir. BMT, bone marrow transplantation; C3G, third-generation cephalosporin; CI, calcineurin inhibitor; FQ, fluoroquinolone; GVHD, graft-versus-host disease; ICU, intensive care unit; MMF, mycophenolate mofetil; MV, mechanical ventilation; NIV, non-invasive mechanical ventilation.

H1N1(v) infection can result in a wide spectrum of clinical patterns, ranging from no symptoms to fulminant viral pneumonia. This new pandemic virus is characterized by a high prevalence of severe viral pneumonitis, which often requires mechanical ventilation \[[@B2]\]. Influenza viruses are known to cause severe infections in immunocompromised patients, of whom variable proportions were reported in epidemiologic descriptions \[[@B2]-[@B4]\]. Our case series is the first to describe the course of H1N1(v) infection in immunocompromised hosts.

Several points deserve to be highlighted. First, the risk factors for H1N1(v) described in the overall population \[[@B2]-[@B4]\] were not found in our cohort. In contrast, none of our patients had obesity (median body mass index 26.9; IQR 21 to 26) or chronic lung disease \[[@B3]\]. Of our 10 patients, 7 were on long-term steroid treatment, as described in the immunocompromised subgroup of the Canadian ICU patients \[[@B3]\]. Cellular immunodeficiency is the main risk factor for lower respiratory tract infection with influenza viruses \[[@B5]\] as the main defense mechanism is CD8 T-lymphocyte-mediated cytotoxicity. The clinical presentation in our patients was similar to that described in immunocompetent individuals, with symptom onset 4 days before ICU admission \[[@B2],[@B4]\]. Mortality was high (40%) compared with the overall population with H1N1 2009 infection \[[@B2]-[@B4]\]. The ICU stay was shorter than in the overall ICU population but the hospital stay was longer, perhaps because of prolonged viral shedding in lymphopenic patients \[[@B5]\].

Abbreviations
=============

ICU: intensive care unit; IQR: interquartile range.
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